VITASPRING BIOMEDICAL CO. LTD. VSBC
Services-Commercial Physical & Biological Research · CIK 0001697884 · Fiscal year ends 0131
Revenue
$0
Fiscal year ended 2026-07-31Operating income
-$161.82K
Fiscal year ended 2026-07-31Free cash flow
—Unavailable
Fiscal year ended 2026-07-31Valuation, from the filing
| Public float | $3.09K | Market value of stock held by non-affiliates, as stated on the cover page for 2022-04-27 |
|---|
| Float per share | $0.00 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2022-04-27, not today.
How this compares in its industry
Percentile among the Services-Commercial Physical & Biological Research filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported revenue of $0 and net income of -$155.82K for the fiscal year ended 2026-07-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VITASPRING BIOMEDICAL CO. LTD.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.
Income
VITASPRING BIOMEDICAL CO. LTD. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
|---|
| Cost of revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross profit | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating income | -$161.82K | -$75.84K | -$81.46K | -$135.73K | -$99.07K | -$69.15K | -$126.49K | -$117.93K | -$218.66K | -$216.83K |
|---|
| Net income | -$155.82K | -$75.84K | -$81.46K | -$142.52K | -$110.84K | -$80.54K | -$143.14K | -$196.29K | -$218.66K | -$216.83K |
|---|
| Research & development | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Weighted-average diluted shares | shares 207.03M | shares 207.03M | —Unavailable | shares 207.03M | shares 207.03M | shares 207.03M | —Unavailable | shares 207.03M | shares 207.03M | shares 207.03M |
|---|
| Pretax income | -$155.82K | -$75.84K | -$81.46K | -$135.73K | -$99.07K | -$69.15K | -$126.49K | -$117.93K | -$218.66K | -$216.83K |
|---|
| Income tax expense | $0 | $0 | $0 | $6.78K | $11.78K | $11.39K | $16.64K | $78.36K | $0 | $0 |
|---|
| Diluted EPS | $0.00 | $0.00 | —Unavailable | $0.00 | $0.00 | $0.00 | —Unavailable | $0.00 | $0.00 | $0.00 |
|---|
| Selling, general & administrative | $5.83K | $75.84K | $81.46K | $135.73K | $6.05K | $69.15K | $126.49K | $117.93K | $218.66K | $216.83K |
|---|
| General & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
VITASPRING BIOMEDICAL CO. LTD. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|
| Cash & equivalents | —Unavailable | —Unavailable | —Unavailable | $0 | $0 | $0 | $0 | $2.06K | —Unavailable | —Unavailable |
|---|
| Total assets | $14.82K | $11.43K | $14.68K | $16.46K | $17.02K | $11.91K | $14.38K | $58.38K | $64.33K | $131.29K |
|---|
| Current assets | $14.82K | $9.77K | $10.53K | $9.83K | $7.89K | $295 | $272 | $41.79K | $45.25K | $64.31K |
|---|
| Total liabilities | $4.68M | $4.52M | $4.45M | $4.37M | $4.22M | $4.11M | $4.03M | $3.93M | $3.77M | —Unavailable |
|---|
| Current liabilities | $2.27M | $4.52M | $4.45M | $4.37M | $4.22M | $4.11M | $4.03M | $3.93M | $3.77M | $3.66M |
|---|
| Total equity incl. NCI | -$4.66M | -$4.51M | -$4.43M | -$4.35M | -$4.21M | -$4.10M | -$4.02M | -$3.87M | -$3.70M | -$3.53M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $0 | $0 | $0 | $0 |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts payable | $0 | —Unavailable | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M | $2.41M |
|---|
Cash flow
VITASPRING BIOMEDICAL CO. LTD. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|
| Operating cash flow | $5.20K | $6.08K | $124 | -$839 | -$1.19K | -$787 | -$1.79K | -$6.44K | -$2.42K | -$4.02K |
|---|
| Capital expenditures | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Investing cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Financing cash flow | $0 | $0 | $0 | $2.00K | $1.98K | $515 | $0 | $2.98K | $6.98K | $4.98K |
|---|
| Net change in cash | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Stock-based compensation | —Unavailable | —Unavailable | $0 | $0 | $0 | $0 | $0 | $27.48K | $41.22K | $41.22K |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | —Unavailable | $2.49K | —Unavailable | $2.49K | $2.49K | $2.49K | $2.49K | $2.49K | $2.49K | $2.49K |
|---|
Derived
VITASPRING BIOMEDICAL CO. LTD. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 |
|---|
| Free cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| SBC / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current ratio | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.02x |
|---|
| Revenue YoY growth | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Net margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| R&D / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VSBC in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.